Women who went on to experience postpartum depression had elevated cortisol levels in their hair during pregnancy, compared with other pregnant women, according to a study published online in PLoS One.
An intravenous drug being developed as a treatment for postpartum depression (PPD) showed positive results in two phase 3 clinical trials, drugmaker Sage Therapeutics announced.
Infusion of brexanolone, an investigational intravenous formulation of allopregnanolone, significantly reduced Hamilton Rating Scale for Depression (HAM-D) scores in women with severe postpartum depression, in a study published online in The Lancet.
A medication commonly given to women during or after labor has been found to be associated with the development of postpartum depression and anxiety.
Data on 21 patients showed that the drug achieved a statistically significant reduction in symptoms at 60 hours, compared to placebo, Sage Therapeutics said.